Hismanal Withdrawal Will Allow Sepracor To Define Metabolite As New Drug
Executive Summary
Janssen's discontinuation of Hismanal prior to the introduction of Sepracor's norastemizole will allow for greater differentiation of the metabolite as a separate product from the parent compound instead of as a follow-on.